Right ventricular adaptation and failure in pulmonary arterial hypertension

John J. Ryan, Jessica Huston, Shelby Kutty, Nathan D. Hatton, Lindsay Bowman, Lian Tian, Julia E. Herr, Amer M. Johri, Stephen L. Archer

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy, characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and vasoconstriction. Although PAH therapies target some of these vascular abnormalities (primarily vasoconstriction), most do not directly benefit the right ventricle (RV). This is suboptimal because a patient's functional state and prognosis are largely determined by the success of the adaptation of the RV to the increased afterload. The RV initially hypertrophies but might ultimately decompensate, becoming dilated, hypokinetic, and fibrotic. A number of pathophysiologic abnormalities have been identified in the PAH RV, including: ischemia and hibernation (partially reflecting RV capillary rarefaction), autonomic activation (due to G protein receptor kinase 2-mediated downregulation and desensitization of β-adrenergic receptors), mitochondrial-metabolic abnormalities (notably increased uncoupled glycolysis and glutaminolysis), and fibrosis. Many RV abnormalities are detectable using molecular imaging and might serve as biomarkers. Some molecular pathways, such as those regulating angiogenesis, metabolism, and mitochondrial dynamics, are similarly deranged in the RV and pulmonary vasculature, offering the possibility of therapies that treat the RV and pulmonary circulation. An important paradigm in PAH is that the RV and pulmonary circulation constitute a unified cardiopulmonary unit. Clinical trials of PAH pharmacotherapies should assess both components of the cardiopulmonary unit.

Original languageEnglish (US)
Pages (from-to)391-406
Number of pages16
JournalCanadian Journal of Cardiology
Volume31
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Pulmonary Hypertension
Heart Ventricles
Pulmonary Circulation
Vasoconstriction
Fibrosis
Mitochondrial Dynamics
Cyclic GMP-Dependent Protein Kinases
Hibernation
Lung
Molecular Imaging
Glycolysis
Adrenergic Receptors
Hypertrophy
Blood Vessels
Down-Regulation
Ischemia
Biomarkers
Clinical Trials
Apoptosis
Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ryan, J. J., Huston, J., Kutty, S., Hatton, N. D., Bowman, L., Tian, L., ... Archer, S. L. (2015). Right ventricular adaptation and failure in pulmonary arterial hypertension. Canadian Journal of Cardiology, 31(4), 391-406. https://doi.org/10.1016/j.cjca.2015.01.023

Right ventricular adaptation and failure in pulmonary arterial hypertension. / Ryan, John J.; Huston, Jessica; Kutty, Shelby; Hatton, Nathan D.; Bowman, Lindsay; Tian, Lian; Herr, Julia E.; Johri, Amer M.; Archer, Stephen L.

In: Canadian Journal of Cardiology, Vol. 31, No. 4, 01.04.2015, p. 391-406.

Research output: Contribution to journalReview article

Ryan, JJ, Huston, J, Kutty, S, Hatton, ND, Bowman, L, Tian, L, Herr, JE, Johri, AM & Archer, SL 2015, 'Right ventricular adaptation and failure in pulmonary arterial hypertension', Canadian Journal of Cardiology, vol. 31, no. 4, pp. 391-406. https://doi.org/10.1016/j.cjca.2015.01.023
Ryan, John J. ; Huston, Jessica ; Kutty, Shelby ; Hatton, Nathan D. ; Bowman, Lindsay ; Tian, Lian ; Herr, Julia E. ; Johri, Amer M. ; Archer, Stephen L. / Right ventricular adaptation and failure in pulmonary arterial hypertension. In: Canadian Journal of Cardiology. 2015 ; Vol. 31, No. 4. pp. 391-406.
@article{943908fc42fc4f4cb7fa433eab80f9f3,
title = "Right ventricular adaptation and failure in pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy, characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and vasoconstriction. Although PAH therapies target some of these vascular abnormalities (primarily vasoconstriction), most do not directly benefit the right ventricle (RV). This is suboptimal because a patient's functional state and prognosis are largely determined by the success of the adaptation of the RV to the increased afterload. The RV initially hypertrophies but might ultimately decompensate, becoming dilated, hypokinetic, and fibrotic. A number of pathophysiologic abnormalities have been identified in the PAH RV, including: ischemia and hibernation (partially reflecting RV capillary rarefaction), autonomic activation (due to G protein receptor kinase 2-mediated downregulation and desensitization of β-adrenergic receptors), mitochondrial-metabolic abnormalities (notably increased uncoupled glycolysis and glutaminolysis), and fibrosis. Many RV abnormalities are detectable using molecular imaging and might serve as biomarkers. Some molecular pathways, such as those regulating angiogenesis, metabolism, and mitochondrial dynamics, are similarly deranged in the RV and pulmonary vasculature, offering the possibility of therapies that treat the RV and pulmonary circulation. An important paradigm in PAH is that the RV and pulmonary circulation constitute a unified cardiopulmonary unit. Clinical trials of PAH pharmacotherapies should assess both components of the cardiopulmonary unit.",
author = "Ryan, {John J.} and Jessica Huston and Shelby Kutty and Hatton, {Nathan D.} and Lindsay Bowman and Lian Tian and Herr, {Julia E.} and Johri, {Amer M.} and Archer, {Stephen L.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.cjca.2015.01.023",
language = "English (US)",
volume = "31",
pages = "391--406",
journal = "Canadian Journal of Cardiology",
issn = "0828-282X",
publisher = "Pulsus Group Inc.",
number = "4",

}

TY - JOUR

T1 - Right ventricular adaptation and failure in pulmonary arterial hypertension

AU - Ryan, John J.

AU - Huston, Jessica

AU - Kutty, Shelby

AU - Hatton, Nathan D.

AU - Bowman, Lindsay

AU - Tian, Lian

AU - Herr, Julia E.

AU - Johri, Amer M.

AU - Archer, Stephen L.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy, characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and vasoconstriction. Although PAH therapies target some of these vascular abnormalities (primarily vasoconstriction), most do not directly benefit the right ventricle (RV). This is suboptimal because a patient's functional state and prognosis are largely determined by the success of the adaptation of the RV to the increased afterload. The RV initially hypertrophies but might ultimately decompensate, becoming dilated, hypokinetic, and fibrotic. A number of pathophysiologic abnormalities have been identified in the PAH RV, including: ischemia and hibernation (partially reflecting RV capillary rarefaction), autonomic activation (due to G protein receptor kinase 2-mediated downregulation and desensitization of β-adrenergic receptors), mitochondrial-metabolic abnormalities (notably increased uncoupled glycolysis and glutaminolysis), and fibrosis. Many RV abnormalities are detectable using molecular imaging and might serve as biomarkers. Some molecular pathways, such as those regulating angiogenesis, metabolism, and mitochondrial dynamics, are similarly deranged in the RV and pulmonary vasculature, offering the possibility of therapies that treat the RV and pulmonary circulation. An important paradigm in PAH is that the RV and pulmonary circulation constitute a unified cardiopulmonary unit. Clinical trials of PAH pharmacotherapies should assess both components of the cardiopulmonary unit.

AB - Pulmonary arterial hypertension (PAH) is an obstructive pulmonary vasculopathy, characterized by excess proliferation, apoptosis resistance, inflammation, fibrosis, and vasoconstriction. Although PAH therapies target some of these vascular abnormalities (primarily vasoconstriction), most do not directly benefit the right ventricle (RV). This is suboptimal because a patient's functional state and prognosis are largely determined by the success of the adaptation of the RV to the increased afterload. The RV initially hypertrophies but might ultimately decompensate, becoming dilated, hypokinetic, and fibrotic. A number of pathophysiologic abnormalities have been identified in the PAH RV, including: ischemia and hibernation (partially reflecting RV capillary rarefaction), autonomic activation (due to G protein receptor kinase 2-mediated downregulation and desensitization of β-adrenergic receptors), mitochondrial-metabolic abnormalities (notably increased uncoupled glycolysis and glutaminolysis), and fibrosis. Many RV abnormalities are detectable using molecular imaging and might serve as biomarkers. Some molecular pathways, such as those regulating angiogenesis, metabolism, and mitochondrial dynamics, are similarly deranged in the RV and pulmonary vasculature, offering the possibility of therapies that treat the RV and pulmonary circulation. An important paradigm in PAH is that the RV and pulmonary circulation constitute a unified cardiopulmonary unit. Clinical trials of PAH pharmacotherapies should assess both components of the cardiopulmonary unit.

UR - http://www.scopus.com/inward/record.url?scp=84961288123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961288123&partnerID=8YFLogxK

U2 - 10.1016/j.cjca.2015.01.023

DO - 10.1016/j.cjca.2015.01.023

M3 - Review article

C2 - 25840092

AN - SCOPUS:84961288123

VL - 31

SP - 391

EP - 406

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

SN - 0828-282X

IS - 4

ER -